Tumor Markers CEA, CA19-9 and CA125 in Monitoring of Response to Systemic Chemotherapy in Patients with Advanced Gastric Cancer

Yamao, Takekazu; Kai, Shunkichi; Kazami, Akira; Koizumi, Koichi; Handa, Takayoshi; Takemoto, Norishige; Maruyama, Masakazu

doi:10.1093/jjco/29.11.550

Cited by 67 publications

(48 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported doubling time estimate, based on the serum level of CEA, agreed with the actual tumor doubling time in 112 previously untreated patients with recurrent gastric cancers [66]. The CEA doubling time ranged from 12 to 105 days, with a mean of 37.5 days.…”

Section: Doubling Time and Lead Time Of Elevated Serum Markerssupporting

confidence: 67%

“…Yamao et al [66] monitored changing patterns in CEA, CA19-9, and CA125 levels during systemic chemotherapy to determine the relationship between changes in the serum tumor marker levels and the response assessment in imaging studies throughout the treatment course. The sensitivity and negative predictive value of falling tumor marker levels after chemotherapy for a partial response in imaging was 100 %.…”

Section: Clinical Significance Of Serum Marker Monitoring During Chemmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

et al. 2013

View full text Add to dashboard Cite

The aim of this review was to evaluate the clinical significance of serum tumor markers, particularly CEA, CA19-9, and CA72-4, in patients with gastric cancer. A systematic literature search was performed using PubMed/MEDLINE with the keywords ''gastric cancer'' and ''tumor marker,'' to select 4,925 relevant reports published before the end of November 2012. A total of 187 publications contained data for CEA and CA19-9, and 19 publications contained data related to all three tumor markers. The positive rates were 21.1 % for CEA, 27.8 % for CA19-9, and 30.0 % for CA72-4. These three markers were significantly associated with tumor stage and patient survival. Serum markers are not useful for early cancer, but they are useful for detecting recurrence and distant metastasis, predicting patient survival, and monitoring after surgery.

show abstract

Section: Doubling Time and Lead Time Of Elevated Serum Markerssupporting

confidence: 67%

Section: Clinical Significance Of Serum Marker Monitoring During Chemmentioning

confidence: 99%

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Yamao et al [6] reported that, in 26 patients with advanced gastric cancer, the survival time of responders assessed by the 4 tumor markers CEA, CA19-9, CA125, and CA72-4 was significantly longer than that of non-responders. In our study, the CA125 response showed an excellent correlation with the reduction of ascites and overall survival.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the 2 common markers CEA and CA19-9, CA125 and CA72-4 have been reported to be elevated in advanced gastric cancer [6]. However, these markers are not all commonly measured, due to the lack of clinical evidence of their value.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

et al. 2011

View full text Add to dashboard Cite

Background Serum tumor markers have been shown to correlate with the clinical status of patients with advanced gastric cancer. However, the clinical significance of each tumor marker in patients with peritoneal dissemination has not been fully verified. Methods Four serum markers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA125, and CA72-4, were periodically measured in 102 patients with peritoneal dissemination who received combination intravenous and intraperitoneal chemotherapy. The initial values at diagnosis and after treatment were analyzed in association with clinicopathological factors, response to chemotherapy, and overall survival. Results The sensitivities of CEA, CA19-9, CA125, and CA72-4 for peritoneal metastasis at the initial diagnosis were 19, 36, 46, and 45%, respectively. The CA125 level was significantly correlated with the degree of peritoneal dissemination and the existence of malignant ascites. Patients with ovarian metastasis showed significantly higher levels of CA72-4. The median survival time of patients with an elevated CA125 level was significantly shorter than that of patients with a normal CA125 level (36.7 vs. 16.6 months, p \ 0.001). Multivariate analysis showed that the degree of peritoneal metastasis and an elevated CA125 level were independent prognostic factors. Normalization of the CA125 level after 3 courses of chemotherapy was correlated with reduced ascites and improved survival.Conclusions Serum CA125 and CA72-4 are clinically useful markers in diagnosis, evaluating the efficacy of chemotherapy, and predicting the prognosis of patients with peritoneal dissemination. From an academic point of view, periodic measurements of these markers are warranted in gastric cancer patients with possible peritoneal dissemination.

show abstract

“…The use of tumor markers has become a very attractive method for the detection and diagnosis of neoplastic diseases, as well as for the monitoring of their course after radical surgery or during chemotherapy 18,19 . One of the challenging problems in the diagnosis and postoperative follow-up of patients with gastric cancer is the low sensitivity of the tumor markers that are currently being used 8 .…”

Section: Discussionmentioning

confidence: 99%

Preoperative serum levels of ca 72-4, cea, ca 19-9, and Alpha-fetoprotein in patients with gastric cancer

et al. 2002

View full text Add to dashboard Cite

INTRODUCTION: The clinical importance of preoperative serum levels of CA 72-4, carcinoembryonic antigen (CEA), CA 19-9, and alpha-fetoprotein (AFP) was prospectively evaluated in 44 patients with gastric cancer. METHOD: The serum tumor marker levels were determined by commercial radioimmunoassay kits. Positivity for CA 72-4 (>4 U/mL), CEA (>5 ng/mL), CA 19-9 (>37 U/mL), and AFP (>10 ng/mL) were correlated according to the stage, histology, and lymph node metastasis. RESULTS AND DISCUSSION: CA 72-4 showed a higher positivity rate for gastric cancer (47.7%) than CEA (25%), CA 19-9 (25%), and AFP (0%). The combination of CA 72-4 with CEA and CA 19-9 increased the sensitivity to 61.4%. The positivity rates of CA 72-4 in patients at stages I and II (initial disease) and in patients at stages III and IV (advanced disease) were 9% and 60.6%, respectively (P < 0.005). No correlation was found between CEA and CA 19-9 levels and the stage of gastric cancer. There was a tendency of positivity for CA 72-4 to suggest lymph node involvement, but it was not significant (P = 0.075). Serum levels of tumor markers did not show a correlation with the histological types of gastric cancer. CONCLUSION: Preoperative serum levels of CA 72-4 provided a predictive value in indicating advanced gastric cancer.

show abstract

Tumor Markers CEA, CA19-9 and CA125 in Monitoring of Response to Systemic Chemotherapy in Patients with Advanced Gastric Cancer

Cited by 67 publications

References 12 publications

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

Preoperative serum levels of ca 72-4, cea, ca 19-9, and Alpha-fetoprotein in patients with gastric cancer

Contact Info

Product

Resources

About